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ABSTRACT 
 
Type I Natural Killer T (NKT) cells are a population 
of innate like T lymphocytes that rapidly respond to a-
GalCer presented by CD1d, via the production of both 
pro and anti-inflammatory cytokines. While 
developing novel a-GalCer analogs that were meant to 
be utilized as potential adjuvants due to their 
production of pro-inflammatory cytokines  (Th1 
skewers), we generated  a-galactosylsphingamides (a-
GSA). Surprisingly, a-GSAs are not potent antigens in 
vivo despite their strong T-cell receptor (TCR)-binding 
affinities. Here, using surface plasmon resonance 
(SPR), antigen presentation assays, and X-ray 
crystallography (yielding crystal structures of 19 
different binary [CD1d–glycolipid] or ternary [CD1d–
glycolipid–TCR] complexes at resolutions between 
1.67 and 2.85 Å), we characterized the biochemical 
and structural details of a-GSA recognition by murine 
NKT cells. We identified a molecular switch within 
murine (m)CD1d that modulates NKT cell activation 
by a-GSAs. We found that the molecular switch 
involves a hydrogen bond interaction between Tyr-73 
of mCD1d and the amide group oxygen of a-GSAs. 
We further established that the length of the acyl chain 
controls the positioning of the amide group with 
respect to the molecular switch and works 
synergistically with Tyr-73 to control NKT cell 
activity. In conclusion, our findings reveal important 
mechanistic insights into the presentation and 
recognition of glycolipids with polar moieties in an 
otherwise apolar milieu. These observations may 
inform the development a-GSAs as specific NKT cell 
antagonists to modulate immune responses. 
 
 
Type I or semi-invariant Natural Killer T (NKT) cells 
are a specialized population of T lymphocytes that 
express a semi-conserved TCR a-chain rearrangement 
(TRAV11/TRAJ18 (Va14Ja18) in mice, 
TRAV10/TRAJ18 (Va24Ja18) in humans) (1). They 
are restricted by the non-polymorphic and non-
classical Major Histocompatibility Class (MHC) I 
analog CD1d and recognize synthetic, self, and 
microbial glycolipid antigens (2-14). NKT cells are 
considered innate like T lymphocytes and respond to 
antigen challenge within 2-4 hours, producing copious 
amounts of both pro- and anti-inflammatory cytokines. 
Many a-GalCer analogs have been studied that induce 
a superior production of IFN-g, often combined with a 
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reduced amount of IL-4 in comparison to a-GalCer 
itself (aka Th1 skewing)(15-17). It has been observed 
that Th1 skewing antigens also lead to increased 
production of IL-12 by the presenting DC, which 
together with IFN-g from the NKT cell trans-activate 
NK cells (18-20). NK cells are the major producers of 
IFN-g at later time points. As such NKT cells are of 
therapeutic interest because they exert a central role in 
bridging the innate and adaptive immune system. The 
mechanism of Th1 cytokine skewing involves TCR 
ligation with CD1d-antigen complexes on DCs, which 
induces upregulation of costimulatory molecules, such 
as CD40L on the NKT cell and CD40 on the DC, 
ultimately leading to DC maturation and IL-12 
production. Several non-mutually exclusive 
mechanisms have been proposed for the Th1 skewing 
activity of various a-GalCer analogs. These involve 
the loading of glycolipids to CD1d located in lipid rafts 
or an increased in vivo half-life of CD1d-glycolipid 
complexes often via enhanced CD1d-glycolipid 
interactions (16,17,21).  
We have previously hypothesized that a-
GalCer analogs that contain aromatic groups to 
enhance binding to CD1d, while not altering TCR 
recognition are superior Th1 skewing antigens (16). In 
one of these glycolipids, NU-a-GalCer, the C6”-OH of 
the galactose was replaced by a naphthyl urea group 
that induced a structural change in the A’ roof of 
CD1d, leading to a cavity in which the aromatic group 
is bound (16). In addition to the two lipid tail 
“anchors”, we proposed this novel interaction as the 
“third anchor” hypothesis (16). Several other a-GalCer 
analogs that had aromatic groups at the 6”-OH of the 
galactose also caused an increased serum IFN-g and 
IL-12 production, albeit not inducing a structural 
change within the A’ roof, but rather mediating 
hydrophobic contacts with CD1d or the TCR (17).  
Other strong Th1 skewing ligands include 7DW8-5, 
containing a terminal aromatic para-fluoro-phenyl 
group in the acyl chain, and other ligands with terminal 
phenyl anchors in the acyl chain that bound within the 
A’ pocket of CD1d are currently being tested as 
vaccine adjuvants  (22-26). The sphingosine chain of 
a-GalCer is the only moiety that had not been 
systematically substituted with aromatic anchors. We 
have recently synthesized a panel of a-GalCer analogs 
in which terminal or in-chain phenyl groups are 
incorporated in the phytosphingosine moiety of short 
chain a-GalCer (PBS-25, (27)) via an amide linker 
(28). These short-chain a-galactosylsphingamides (a-
GSA) were bound by the TCR with high affinity, yet 
did not induce a robust cytokine production when 
administered to mice by intraperitoneal injection (28). 
However, when increasing the length of the acyl chain 
to 26 carbons, a-GSAs induced the production of both 
the pro- and anti-inflammatory cytokines IL-4 and 
IFN-g respectively,  albeit at markedly reduced levels 
compared to a-GalCer (28). In the current study, we 
have systematically analyzed these a-GSAs with 
regard to the TCR binding kinetics and their ability to 
activate a murine iNKT cell hybridoma. We also 
determined the crystal structures of 19 different binary 
(CD1d-glycolipid) or ternary (CD1d-glycolipid-TCR) 
complexes in an effort to unravel the molecular basis 
of the reduced antigenicity of the a-GSAs. We have 
discovered that the activity of a-GSAs is regulated by 
an interplay of acyl chain length and a molecular 
switch within CD1d that forms a novel interaction with 
the amide group in the phytosphingosine of a-GSAs.  
 
 RESULTS 
a-galactosyl sphingamide overview- We have 
previously reported a novel class of a-GalCer 
derivatives termed a-galactosylsphingamides 
(aGSAs) or in short sphingamides (28). The 
sphingamides are similar to a-GalCer but feature an 
amide group within the sphingosine moiety at a fixed 
distance from the anomeric carbon (Figure 1). This 
amide was used to introduce either a terminal or in-
chain phenyl group in the sphingosine. The acyl chain 
length was varied from eight to twenty-six carbons. We 
have synthesized various control compounds that 
mimic the overall structure of the sphingamides but 
lack the central amide group to assess the influence of 
this polar moiety in NKT cell activation.  
 
SPR studies using the Va14Vb8.2 TCR (clone 
2C12)- In analogy to our previous study (28), all 
sphingamides with a terminal phenyl group were 
bound by the Va14Vb8.2 TCR with similar high 
affinities in the range from 16 to 37 nM (Figure 2). 
There were no significant differences between the TCR 
association and dissociation rates. However, the 
sphingamide aGSA[26,P5p], which has a C26 fatty 
acid and an in-chain para-substituted phenyl moiety 
was bound by the TCR with considerably weaker 
affinity, suggesting that the phenyl moiety impairs 
TCR binding to CD1d. We have not measured the TCR 
binding affinities for all sphingamides or control 
compounds, since our selected lipids establish a similar 
TCR binding recognition. However, we failed to detect 
any TCR binding to aGSA[8,2P] and aGSA[8,4P], 
suggesting that these relatively short sphingamides do 
not bind to CD1d. This is also corroborated by our 
inability to obtain crystal structures of these two lipids 
in complex with CD1d (see below). 
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iNKT cell activation by sphingamides- 
Previously we reported that sphingamides are not 
potent agonists for murine iNKT cells in vivo (28). 
Therefore, we have assessed in detail the antigenicity 
of sphingamides using a cell free and cell-based 
antigen presentation assay. Surprisingly, despite their 
high TCR binding affinity, none of the short acyl chain 
sphingamides were able to robustly activate the iNKT 
cell hybridoma 1.2 when presented by recombinant 
mouse CD1d, suggesting that solely varying the 
position of the phenyl anchor does not affect 
antigenicity (Figure 3A). In contrast, short acyl chain 
a-GalCer (aGC[8,18]) strongly activated iNKT cells. 
We next investigated whether the sphingamide 
modification influenced loading in cellular 
compartments and presentation by CD1d. Therefore, 
we used a cell-based antigen-presentation assay in 
which A20 cells were transfected with either wild-type 
or “tail-deleted” mCD1d (Figure 3B and C). The “tail 
deleted” mCD1d lacks the tyrosine containing 
trafficking motif within the cytoplasmic tail and 
prevents its recycling through lysosomal 
compartments after mCD1d has been expressed on the 
cell surface, while wild-type mCD1d can recycle 
through lysosomal compartments allowing for lipid 
loading and/or processing. Again, none of the short-
chain sphingamides activated iNKT cells, regardless of 
whether mCD1d had access to lysosomes for potential 
sphingamide loading using lipid transfer proteins. To 
increase the binding affinity of the sphingamides to 
mCD1d, we then synthesized and analyzed the two 
full-length sphingamides aGSA[26,18P] and 
aGSA[26,2P5p]. Surprisingly, both lipids potently 
activated iNKT cells and the response was optimal 
already at the lowest lipid concentration (0.5 µg/ml), 
despite aGSA[26,2P5p] having a 10-fold reduced 
TCR binding affinity (Figure 2 and 3D). The antigen-
presentation data led us to hypothesize that the acyl 
chain length influences iNKT cell activation by 
sphingamides and, therefore, we have also generated 
and included intermediate acyl chain aGSAs (C12, 
C16, and C20) in our subsequent studies. Theses 
aGSAs were based on the sphingamide 6P backbone.  
 
Sphingamide presentation by CD1d- In order 
to rationalize why all sphingamides are bound by the 
iNKT TCR with high affinity, but only long acyl chain 
sphingamides potently activate iNKT cells, we 
examined the structural basis of sphingamide 
presentation by mCD1d. The individual crystal 
structures of mCD1d-sphingamide complexes were 
determined to resolutions between 1.67 Å and 2.45 Å 
(Table S1). The two short-chain sphingamides 
aGSA[8,6P] and aGSA[8,8P] had been crystallized 
previously (termed as 5d and 5e in (28)). Most 
sphingamides show well-defined electron density for 
the hydroxyls of both the sugar moiety and the lipid 
backbone, indicative of an ordered presentation by 
CD1d (Figure 4).  
The exception was aGSA[12,6P], which 
showed well-defined electron density for the galactose 
but less ordered electron density around the amide 
group, suggesting a more flexible binding of that 
portion. As expected for a-GalCer analogs, the acyl 
chain is always inserted into the A’ pocket, regardless 
of its length, while the sphingosine moiety containing 
the amide group is bound in the F’ pocket. Up to an 
acyl chain length of C12, all sphingamides also 
recruited a spacer lipid into the A’ pocket of CD1d. 
Interestingly the helical orientation of the acyl chain 
circling in the A’ pocket differs between the longer 
sphingamides aGSA[20,6P] and aGSA[26,6P]. While 
aGSA[20,6P] circles clockwise when looking down at 
the pocket, aGSA[26,6P] circles in a counter-
clockwise fashion. Whether there is a functional 
consequence of the acyl chain binding orientation is 
not known.  
The sphingamide aGSA[8,6P] was structure-
based designed and predicted to form an additional 
hydrogen-bond between its amide oxygen and the 
hydroxyl of mCD1d residue Tyr73. Surprisingly, only 
the long chain sphingamide aGSA[26,6P] exhibited 
this H bond, while the amide group of the shorter 
homologues and other sphingamides exhibit an altered 
orientation (Figure 5). It appears there is a high degree 
of rotational freedom for this group, with the amide 
oxygen either pointing towards or away from Tyr73. 
However, since the electron density in that region is 
well-defined for most sphingamides, we propose that 
the acyl chain length influences the precise positioning 
of the amide group in the F’ pocket, which in turn 
influences iNKT cell activation. Except for the amide 
group, the sphingamides bound in a conserved 
orientation with the galactose being stabilized by a 
core hydrogen bond network involving CD1d residues 
Asp80, Asp153, and Thr156 and the 2”-OH, 3”-OH of 
the galactose as well as the 3’- and/or 4’ hydroxyls of 
the phytosphingosine chain. The only exception is 
aGSA[20,6P] which showed a slight rotation in the 
galactose positioning. This binding orientation resulted 
in the loss of the H bond interaction between Asp153 
of CD1d and 2”-OH and 3”-OH of the galactose, while 
a new H bond is formed with the 4”-OH. However, the 
electron density for the galactose of this ligand is less 
contoured compared to other sphingamides, suggesting 
some flexibility in the binding orientation, especially 
since there is no well-defined electron density for the 
galactose hydroxyls (Figure 4). 
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TCR recognition of sphingamides- Since we 
had previously established that the TCR of iNKT cells 
can induce a structural change in both glycolipid as 
well as mCD1d upon binding (29), we also determined 
the crystal structures of a panel of sphingamides 
presented by mCD1d and in complex with the 
Va14Vb8.2 TCR (clone 2C12) at resolutions between 
2.0 Å and 2.85 Å (Table S1). The TCR binds above 
mCD1d in the canonical parallel binding orientation, 
with the complementarity-determining region (CDR) 
1a sitting above the galactose of the glycolipids and 
CDR3a binding centered above the F’ pocket of 
CD1d. CDR3a both contacted the glycolipid ligand, as 
well as the F’ roof using the hydrophobic finger 
Leu99a (Figure 6).  
The electron density of each glycolipid is 
unambiguous, even in the lower resolution structures 
and is a consequence of the TCR stabilizing and 
locking the binding orientation of the glycolipids 
inside the CD1d binding groove. A close examination 
of the CD1d-glycolipid, as well as TCR-glycolipid 
interactions reveals no differences between the 
different sphingamides, in contrast to the binary 
complexes, in which the sphingamides bind differently 
to mCD1d with respect to the positioning of the amide 
group in the phytosphingosine-like moiety. The TCR 
forms the canonical hydrogen bond interactions, 
especially Gly96a with the 2”-OH and Asn31a with 
the 3”- and 4”-OH groups of the galactose, while 
Arg95a contacts Asp80 of CD1d (Figure 7). In the 
ternary complexes, all sphingamides, regardless of 
whether they contain a central or terminal phenyl 
attached to the amide group within the 
phytosphingosine-like moiety, now form an additional 
H bond between the hydroxyl of Try73 of CD1d and 
the amide oxygen of the sphingamides. This suggests 
that upon TCR binding, the TCR forces each 
sphingamide into a conserved binding orientation, the 
hallmark of which is the formation of this novel H bond 
interaction.  
 
Identification and characterization of a 
molecular switch in CD1d- Given the fact that the long 
chain sphingamide agonist aGSA[26,6P] has the 
identical binding orientation in the ternary complex 
compared to the inactive short chain sphingamide 
aGSA[8,6P], we compared the binding orientation 
before and after TCR binding for all crystallized 
sphingamides (Figure 8A and B). Surprisingly, only 
the active sphingamide aGSA[26,6P] shows the 
additional H bond with Tyr73 of CD1d in the absence 
of TCR binding (Figure 8A), while all sphingamides 
form this H bond upon TCR binding (Figure 8B). This 
led us to speculate that the length of the acyl chain 
determines the binding orientation of the amide group 
in the F´ pocket of CD1d, and whether or not it is 
further stabilized by the additional H bond with Tyr73. 
We hypothesize that this interaction forms a molecular 
switch that affects sphingamide activity. A preformed 
H-bond (in the absence of TCR) resembles an active 
state (“switch ON”), while lack of this H bond will lead 
to an inability of activating iNKT cells (“switch OFF”). 
A systematic analysis of a panel of sphingamides with 
increasing acyl chain length revealed a direct 
correlation between acyl chain length and antigenicity. 
The short C8 acyl chain failed to robustly activate an 
iNKT cell hybridoma in a cell-free antigen 
presentation assay using recombinant mCD1d, while 
the antigenicity successively increases with increasing 
acyl chain length (Figure 8C). This suggests that the 
presence or absence of the pre-formed H bond 
involving Tyr73 are the two extreme states (ON vs. 
OFF) and that the acyl chain length modulates the 
overall intrinsic activity of sphingamides. We have 
further tested the influence of the H-bond by site-
directed mutagenesis of the molecular switch (Tyr73).  
Tyr73Phe-modified CD1d retains its overall structure 
and interaction with sphingamide, while excluding H 
bond bond formation with the amide. With the 
exception of the long chain sphingamide 
aGSA[26,6P], the activity of all sphingamides is 
markedly reduced, suggesting that the H bond 
stabilizes the binding orientation of the amide group 
within CD1d after TCR binding to allow for potent 
iNKT cell activation. However, the H bond itself is not 
the only driver of activity. The acyl chain length itself 
dictates the binding orientation of the amide group 
even in the absence of this stabilizing H bond. The 
Tyr73Phe mutant also showed slightly decreased 
cytokine production by the control antigen aGC[8,18] 
but not to the extend observed for the sphingamides. 
We next speculated that modifying the molecular 
switch to stabilize the orientation of the amide group in 
the “ON position” would increase antigenicity. Hereto, 
we generated the mutant mCD1d Tyr73His. Indeed, all 
sphingamides now show hyperactivity, even the 
otherwise inactive short chain aGSA[8,6P], while in 
contrast the activity of the control antigen was greatly 
reduced (~4-fold) (Figure 8C). This suggests that 
introducing a polar group into an apolar environment 
(the hydrophobic F’ pocket of CD1d) reduces the 
activity of traditional hydrophobic glycolipid antigens, 
while it is beneficial for engineered glycolipids that 
contain polar groups within the sphingosine chain.  
The polarity likely stabilizes the amide group 
and positions it away from the F’ roof, which is the 
major binding site of the TCRa chain, especially the 
hydrophobic finger Leu99a, which was shown to be 
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crucial for iNKT cell activation (30). If our hypothesis 
holds true, we would expect that the inactive 
sphingamide aGSA[8,6P] now forms the additional H 
bond with His73 in the mCD1d Tyr73His mutant 
before TCR binding, leading to an active complex. We 
have, therefore, determined the crystal structure of the 
mCD1d Tyr73His/aGSA[8,6P] complex (Table S1 
and Figure 8D). As expected, aGSA[8,6P], which had 
the amide oxygen pointing away from the hydroxyl of 
Tyr73 in wildtype CD1d (“switch OFF”) (Figure 8A, 
yellow lipid), now features a rotated amide group to 
form an H bond with His73 (“switch ON”). Electron 
density in that region is unambiguous, however, the 
introduction of polarity in the F’ pocket slightly affects 
binding of the terminal acyl chain carbons in the A’ 
pocket, for which electron density becomes disordered.  
In summary, two factors appear to drive 
sphingamide activity. The acyl chain length, which 
dictates amide positioning within CD1d and the ability 
to form a stabilizing interaction with Tyr73 to lock the 
binding orientation of the amide group in an active 
state.        
 
DISCUSSION 
In this study, we have characterized a panel of 
a-GalCer analogs termed a-galactosylsphingamides 
that contain a phenyl group connected to the 
phytosphingosine moiety via an amide linker. The 
rationale was that the phenyl groups would act as an 
anchor to increase the binding interaction with CD1d, 
while not affecting the interaction with the TCR of 
iNKT cells. Unexpectedly, although the TCR bound 
the sphingamides with high affinity, short acyl chain 
(C8-C12) aGSAs failed to activate iNKT cells in vitro 
and in vivo, while long acyl chain aGSAs conferred 
antigenicity. The obvious conundrum was that both 
short chain (inactive) and long chain (active) aGSAs 
showed no difference in the TCR binding kinetics, as 
determined by surface plasmon resonance studies 
using recombinant molecules in solution. Even though, 
this assay does not account for other interactions (e.g. 
co-receptor binding, formation of the immunological 
synapse) that would occur in vivo upon antigen 
recognition, previous studies on NKT cells observed a 
correlation between the 2D-TCR binding affinity and 
the cytokine production (5,7,31-33). By determining 
the crystal structures of various aGSAs and control 
compounds before and after TCR binding we identified 
a molecular switch that controls the antigenicity of 
aGSAs, yet does not affect the TCR binding kinetics. 
The molecular switch is formed between the amide 
oxygen of the aGSAs and Tyr73 of CD1d and 
controlled by the acyl chain length of the ligands. This 
molecular switch has an “ON” and “OFF” position 
before TCR binding, which correlates with the 
subsequent ability to activate NKT cells. Considering 
that there is no difference in the TCR binding kinetics 
between inactive and active aGSAs, we speculate that 
a compensatory mechanism is masking the biophysical 
properties leading to the observed biological 
differences. The active sphingamide aGSA[26P5p] 
with an in-chain phenyl group is an outlier, since it 
lacks the pre-formed H bond with Tyr73 but also has 
reduced TCR binding affinity. Previously we had 
reported that the TCR association rate toward CD1d-
glycolipid complexes is affected by the positioning of 
the galactose moiety (29). Since a-GalCer is already 
presented in the ideal orientation, a fast TCR 
association rate is observed, while ligands that need to 
undergo a re-orientation of the sugar upon TCR 
binding have a slower association rate(29). TCR 
dissociation is affected by whether the F’ roof is open 
or closed before TCR binding (29). For aGSAs, TCR 
binding positioned the amide group in a way that the 
amide oxygen formed the novel H bond interaction 
with Tyr73 of CD1d. We believe that this interaction 
stabilized TCR binding (and reduced dissociation), 
since CD1d itself contributed binding energy to keep 
the amide group in place. As such, we did not see 
reduced TCR dissociation. A similar scenario was 
reported for a-glycosyl diacylglycerolipids from S. 
pneumoniae in comparison to a-galactosyl 
diacylglycerolipids from B. burgdorferi. Here, the 
TCR dissociated much slower from the glucose 
containing ligand compared to the galactose containing 
ligand (34). This was likely due to a novel contact 
formed between the glucose-specific axial 4”-OH and 
Thr156 of CD1d, which cannot be formed with the 
galactose version (34). Overall, the binding affinity 
between both galactose and glucose antigens was 
similar.  
Interestingly, a similar phenomenon was 
recently described for peptide-(p)MHC restricted 
TCRs. Here, TCRs were also found to bind with high 
affinity to pMHC complexes, yet this binding event did 
not lead to T cell activation (35). Using single-
molecule force measurements, the authors 
demonstrated the emergence of catch bonds in the 
activating pMHC-TCR interface, while non-agonist 
peptides formed slip bonds with the same TCR under 
force, which accounted for the differences in T cell 
activation (35).  
Recently p-MeOBz amide-containing a-
GalCer analogs have been reported that contain 
aromatic groups within the acyl chain but also carry an 
amide linker, as well as an additional oxygen following 
the aromatic group. The polar amide was designed to 
interact with a region in the A´ pocket of CD1d that for 
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a slightly polar side pocket (Ser28 and Gln14) (36). 
Surprisingly, the incorporation of polar groups within 
the acyl chain results in a Th2 polarized NKT cell 
response characterized by a reduced production of 
IFN-g and increased levels of IL-4. Therefore, the 
incorporation of polar moieties in an otherwise apolar 
glycolipid antigen is a novel strategy for modulation 
NKT cell responses but the outcome of the associated 
immune response is difficult to predict at this point. 
The sphingamides are also of interest for the 
development of NKT cell antagonists, if their binding 
affinity towards CD1d can be increased, without 
leading to antigenicity. Such a sphingamide would 
contain the short acyl chain (for inactivity) but 
introduce a third anchor, such as we have identified in 
the glycolipid NU-a-GalCer (16). Development of 
NKT cell antagonists using short chain sphingamides 
as a scaffold are currently ongoing.   
 
 
EXPERIMENTAL PROCEDURES 
 
Protein expression and purification- Mouse 
CD1d/b2M was expressed in Spodoptera frugiperda 
(Sf9) insect cells using the baculovirus expression 
system and purified as previously reported (5). The 
Va14Vb8.2 TCR from the iNKT cell hybridoma 2C12 
was generated by expressing the separate TCR a and b 
chains in E. coli and refolding from inclusion bodies as 
reported (5).     
 
Lipid synthesis- a-Galactosylceramides 
containing either a C8 or C26 fatty acyl chain and 
sphingosine chains of varying length with terminal 
phenyl moieties were synthesized as reported (37). a-
Galactosylsphingamides were synthesized as 
previously reported (28). Structural representations of 
all lipids are found in Figure 1. 
 
Surface Plasmon Resonance studies- For 
kinetic experiments, enzymatically biotinylated CD1d 
(C-terminal birA tag) was used for lipid loading (see 
next chapter). Individual CD1d-glycolipid complexes 
were immobilized on a CAP sensor chip (GE 
Healthcare, Chicago, IL) at levels between 100-400 
response units using a Biacore T200. Increasing 
concentrations of TCR (15 nM to 1 µM) in HBS-EP 
buffer (10 mM HEPES, 150 mM NaCl, 3 mM EDTA 
and 0.05% surfactant Tween 20) were passed over the 
sensor chip at a flowrate of 30 µl/min, without 
regenerating the sensor chip surface in between cycles. 
Association was observed for 4 min, while dissociation 
was continued for up to 15 min. All binding curves 
were corrected for background and bulk refractive 
index contribution by subtracting the response of the 
reference flow cells from the active surface. Kinetic 
data were analyzed using the Biacore T200 Evaluation 
software 2.0 (GE Healthcare, Chicago, IL) using a 1:1 
Langmuir interaction kinetic model in order to 
calculate the association rate (ka) and the dissociation 
rate (kd) and the equilibrium dissociation constant (KD 
= kd/ka) by non-linear fitting. Kinetic experiments were 
performed at least twice with 2 different TCR 
preparations.   
 
Antigen presentation assay- The cell-free 
antigen-presentation assay has been performed as 
reported (38). 96-well plates were coated with 1 µg of 
CD1d and incubated overnight at RT with three 
different concentrations of glycolipids as triplicates. 
Buffer was removed and hybridoma cells (5x104) in 
culture media were added to each well and co-
incubated with CD1d-glicolipid complexes overnight 
at 37˚C in a CO2 incubator. The cell-based antigen-
presentation assay also has been described (39). 
Briefly, antigen-presenting cells (1x105 per well) were 
pulsed with indicated amounts of glycolipid and were 
incubated overnight. The cells were then combined 
with 5x104 cells of the Va14Vb8.2 NKT cell 
hybridoma DN3A4-1.2 (1.2) for 24 h. The 1.2 type I 
NKT hybridoma cell line has been described 
previously (40). TCR stimulation and T cell activation 
was measured using a sandwich ELISA for IL-2 
cytokines in the supernatant of hybridoma cultures.  
 
Lipid loading, complex formation and 
crystallization- Mouse CD1d was incubated with a 6-
10 fold molar excess of glycolipids (dissolved in 
DMSO at 10 mg/ml) in 50 mM Hepes pH 7.5, 150 mM 
NaCl and incubated over night at room temperature 
(RT) under slight agitation. For structural analysis of 
CD1d-glycolipid complexes, the CD1d/lipid mixture 
was spun down (14,000 g at 4˚C for 10 min), 
concentrated using 30 kDa molecular filtration devices 
and purified further by size exclusion chromatography 
using a Superdex S-200 GL10/300 column. For 
structural analysis of CD1d-glycolipid-TCR 
complexes, the CD1d-lipid mixtures were incubated 
for 2h at RT with purified TCR at 2-fold molar excess 
of CD1d, concentrated to ~250 µl and subjected to 
SEC to separate ternary complexes from unbound 
CD1d and TCR using a Superdex S-200 GL10/300. 
Fractions containing CD1d-glycolipid or CD1d-
glycolipid-TCR complexes were pooled, concentrated 
to ~5 mg/ml in 10 mM HEPES pH 7.5, 30 mM NaCl 
and subjected to crystallization trials using the sitting 
drop vapor diffusion method. Typically, 1 µl of protein 
solution was mixed with 1 µl precipitant using selected 
conditions of the PEG/ION screen that previously 
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yielded crystals of related CD1d-glycolipid or CD1d-
glycolipid-TCR complexes. Plates were incubated at 
22.3˚C for several days (ternary complexes) or 1-2 
weeks (CD1d-glycolipid) before harvesting individual 
crystals for diffraction analysis. Crystallization 
conditions for each individual complex are listed in 
Table S1. 
 
Data collection and structure determination- 
Single crystals were cryo-protected by immersion in 
crystallization solution containing 20-25% glycerol 
and flash cooled in liquid nitrogen. Diffraction data 
were collected remotely at beam line 7-1, 14-1 and 9-
2 at the Stanford Synchrotron Radiation Light source 
(SSRL, Menlo Park, CA). Diffraction data for the 
individual crystals were processed and scaled using 
HKL2000. All structures were determined by 
molecular replacement method using the protein 
coordinates from the mCD1d-iGb3 structure (PDB ID 
2Q7Y) and in case of ternary complexes also the TCR 
coordinates (PDB ID 3QUZ) using PHASER (41) as 
part of the CCP4 suite (42). The models were built in 
COOT (43) and iteratively refined using REFMAC5 
(44).Refinement progress was monitored by a 
continuous drop in Rfree values and improvement in 
electron density. Data collection and refinement 
statistics are presented in Table S1. The quality of the 
models was examined using Molprobity (45). Crystal 
structure illustrations were prepared using 
MacPyMOL (Schroedinger, New York City, NY). 
 
Accession numbers. The coordinates and 
structure factors of the various complexes have been 
deposited in the Protein Data Bank (www.rcsb.org), 
under the accession codes listed in Table S1.  
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FIGURE LEGENDS 
 
 
Figure 1. Overview of glycolipids. Sphingamides (aGSAs) (middle panel) were structurally derived from the 
short chain a-GalCer analog (aGC[8,18]) with increasing alkyl chain length between the terminal phenyl anchor 
and the amide group. The aGSA was then selected and variants synthesized with acyl chain length from C12 to 
C26 (left panel). Control a-GalCer analogs with terminal phenyl anchors lacking the amide group were also 
prepared (right column). Bottom row, aGSAs that have a short or long acyl chain and a central phenyl anchor. 
 
Figure 2. TCR binding kinetics. SPR sensorgrams are shown as red curves with fitted data (1:1 Langmuir 
interaction) shown as black curves. TCR concentrations are indicated and inset show the kinetic data including 
TCR association rate (ka), TCR dissociation rate (kd) and equilibrium binding constant (KD). Each binding 
experiment was performed at least twice with 2 different TCR preparations. One representative sensorgram is 
shown. 
 
Figure 3. NKT cell activation by sphingamides. Short chain aGSAs were assessed for their ability to induce IL-
2 production by the murine NKT cell hybridoma 1.2 when added to recombinant mCD1d (A), or when added to 
A20 cells that were transfected with either tail-deleted CD1d (B), or wildtype CD1d (C). IL-2 was measured in 
the supernatant using ELISA. GalGalCer was used as a control for CD1d trafficking through the lysosome. D, 
same as A but including long chain aGSAs and a higher antigen concentration dose. Experiments were performed 
at least 3 times with one representative experiments shown. 
 
Figure 4. Glycolipid binding orientation in mCD1d. Overview of the CD1d-glycolipid structure (top left). Side 
view of the CD1d binding groove with the a2-helix removed for better view. CD1d in grey cartoon, glycolipids 
as yellow sticks, and colored by atom type. Several CD1d residues that are responsible for lipid binding are 
depicted. Electron density (2FoFc at 1s) is shown only for the glycolipids. Spacer lipid shown in green. 
 
Figure 5. H bond network between CD1d and glycolipids. Detailed view into the binding groove of CD1d (grey 
cartoon), with glycolipids as yellow sticks and colored by atom type. CD1d residues that form H bond interactions 
with the antigen are depicted. H bonds shown as dashed blue lines (3.5 Å distance cut-off). Spacer lipid shown in 
green. Note that the novel H bond is only formed between the hydroxyl of Try73 of CD1d and the amide oxygen 
of the agonist aGSA[26,6P].  
 
Figure 6. Overview of ternary complex structures with electron density for the glycolipids. Similar view and 
coloring as Figure 4 but with TCR a-chain shown as cyan cartoon and TCR b-chain shown as orange loops (not 
contacting the antigen). CDR1a and 3a sit above the glycolipid.  
 
Figure 7. H bond interactions between TCR and glycolipid. Same color scheme as in Figure 5. TCR depicted as 
in Figure 6. Note that the novel H bond is formed between the hydroxyl of Try73 of CD1d with the amide oxygen 
in all sphingamide structures.  
 
Figure 8. Molecular switch Tyr73 of CD1d modulates aGSA activity. Sphingamide binding comparison before 
(A) and after (B) TCR binding. aGSA (in different colors) are superimposed within the CD1d binding groove. 
aGSA[8,6P] in yellow and aGSA[26,6P] in cyan. aGSA[20,6P] in orange. Before TCR binding the sphingosine 
moiety of aGSA[26,6P] sits slightly deeper in the CD1d F´ pocket and forms the novel H bond with Tyr73. All 
aGSAs superimpose very well after TCR binding, with the only difference being the different acyl chains (B). 
Antigen-presentation assay by recombinant wildtype mCD1d or the mutants Y73F or Y73H similar to Figure 3. 
Increasing the acyl chain length from C8 to C26 increases the antigenicity of aGSAs. D. Crystal structure of the 
hyperactive mCD1d mutant Y73H bound to aGSA[8,6P] show the molecular switch in the “ON” position, 
correlating with the observed activity in panel C (right). 
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